| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 15.6 | 9.0 |
| Gross profit | 13.0 | 7.2 |
| Profit before tax | -17.3 | -11.4 |
| Net income | -17.3 | -11.4 |
| EPS (diluted, $ a share) | $-0.52 | $-13.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +73.3% |
|---|---|
| Gross margin | 83.2% |
| Operating margin | -118.7% |
10-Q filed with the SEC, NASDAQ: MOBI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mobia Medical, Inc.: key numbers
- Share price
- $12.61Close, Nov 17
- Market cap
- $420M
- Shares outstanding
- 33.33MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mobia Medical, Inc.
All →Mobia Medical Financial Results
Mobia Medical reported Q3 2026 revenue of $15.6 million, a 73% year-over-year increase driven by broader adoption of its Vivistim System. The company also raised its full-year 2026 revenue guidance to a range of $57.0 million to $57.5 million, reflecting strong commercial execution and territory expansion.
- Term
- Q3 2026
“This quarter, we delivered our strongest results yet. Revenue growth of 73% reflects the strength of our commercial execution and the predictable nature of our patient funnel.”
Richard Foust, President and Chief Executive Officer
“Additionally, we were pleased to announce the inclusion of paired VNS in the updated AHA Stroke guidelines for 2026, serving as validation of our evidence-based approach to stroke recovery and further recognition of how Vivistim® Paired VNS™ Therapy can redefine what is possible for stroke survivors.”
Richard Foust, President and Chief Executive Officer
Mobia Medical Leadership Change
Mobia Medical, Inc. appointed Myriam J. Curet, M.D., to its nominating and corporate governance committee, effective October 15, 2026. This filing is an amendment to a previous 8-K to finalize her committee assignment following her earlier election to the Board of Directors.
Mobia Medical Leadership Change
Mobia Medical, Inc. announced that the Board of Directors appointed Dr. Reza Zadno to its audit committee, effective October 15, 2026. Dr. Zadno, who was previously elected to the Board, will also continue to serve on the company's compensation committee.